Ondine raises £10M to push Steriwave toward US filing

Ondine Biomedical completed a £10 million fundraising to extend runway into 2028 and fund its planned US regulatory push for Steriwave, its nasal photodisinfection treatment. The raise follows Phase 3 data showing a lower risk of surgical site infections and comes as the company expands use in approved markets outside the US.

Why it matters: - Ondine Biomedical now has funding to keep operations going through key US regulatory steps and ongoing commercial rollout in approved markets. - Steriwave targets hospital-acquired infections, a major burden for surgical and critical care patients. - The company is betting that Phase 3 results and broader international adoption will support a future US filing.

What happened: - Ondine Biomedical completed a £10 million fundraising on London’s AIM market. - The raise was priced at a premium to the company’s pre-announcement closing share price. - All directors supported the financing. - Chief Executive Officer Carolyn Cross subscribed for about 10% of the issue, or about £1.06 million / C$2.0 million. - Ondine said the net proceeds extend its operational runway through early 2028. - The company is using the capital to advance its planned US regulatory submission and expand Steriwave commercialization in approved international markets.

The details: - Steriwave is Ondine’s light-activated antimicrobial therapy for nasal decolonisation. - The treatment is designed to reduce surgical site infections and infections in ICU settings. - Ondine is preparing for a US FDA pre-submission meeting in Q1 2027. - The company is targeting a New Drug Application submission for mid-2027. - The financing follows topline results from the Phase 3 LANTERN trial. - LANTERN included 5,188 surgical patients across 18 centers. - The trial met its primary efficacy endpoint. - The primary Bayesian analysis showed an estimated 40.5% lower risk of surgical site infections within 30 days. - The same analysis showed a 98.2% posterior probability of treatment benefit versus standard of care. - Exploratory frequentist analyses were consistent with the Bayesian result, with p<0.05. - Ondine said the full study dataset is being finalized ahead of the FDA meeting. - Steriwave is a five-minute, nurse-administered treatment that fits into pre-surgical workflow. - The treatment uses non-thermal red light and a photosensitizing formulation in the nose to generate reactive oxygen species that disrupt microbial membranes and macromolecules. - Ondine said pre-clinical investigations have shown no evidence of induced microbial resistance.

Between the lines: - The financing reduces near-term capital pressure and gives Ondine time to convert clinical data into a regulatory strategy. - The premium-priced raise and board participation suggest internal confidence in the US pathway and the commercial case. - The company is leaning on a broader evidence base in Canada, the UK and other authorized markets to support adoption and future market access. - The regulatory path remains a forward-looking process, so the clinical results do not guarantee FDA approval.

What’s next: - Ondine will finalize the LANTERN dataset for the FDA pre-submission meeting in Q1 2027. - The company is targeting a mid-2027 NDA submission. - Commercial deployments and clinical evaluations are continuing in Canada, the UK, Europe, Mexico and Australia. - Ongoing pilots are underway in Latin America, continental Europe and Switzerland. - Additional investigator-led studies in authorized markets are continuing to expand the clinical evidence base.

The bottom line: - Ondine has bought time, cash and momentum as it tries to turn Steriwave’s international traction and Phase 3 results into a US regulatory filing.